JAIME L WIEBEL
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism DALLAS, TX NPI 1598080228
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism TX Novo Nordisk AS All categories
General Payments — all program years on this page
$14,363.03
- Category: General Payments
- Program years: PY2018–2024
- Record count: 650
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,709.17 across 84 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,709.17 | 84 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $252.75 | 13 |
| Insulet Corporation | $143.99 | 7 |
| SANOFI-AVENTIS U.S. LLC | $130.82 | 5 |
| DEXCOM, INC. | $105.65 | 4 |
| MannKind Corporation | $94.77 | 5 |
| ABBVIE INC. | $83.60 | 5 |
| Lilly USA, LLC | $68.93 | 4 |
| Corcept Therapeutics | $65.23 | 3 |
| Ascendis Pharma Inc | $65.07 | 4 |
| Xeris Pharmaceuticals, Inc. | $64.87 | 3 |
| Averitas Pharma Inc. | $58.35 | 2 |
| Radius Health, Inc. | $49.96 | 3 |
| CHIESI USA, INC. | $47.64 | 2 |
| Neurocrine BioSciences, Inc. | $46.02 | 2 |
| CeQur Corporation | $42.48 | 1 |
| Alvogen Inc | $36.90 | 2 |
| PFIZER INC. | $36.50 | 2 |
| IBSA Pharma Inc. | $36.35 | 2 |
| Amneal Pharmaceuticals LLC | $34.37 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33.67 | 2 |
| Tandem Diabetes Care, Inc. | $33.67 | 1 |
| Avvisto Therapeutics, LLC | $32.54 | 2 |
| Medtronic, Inc. | $31.71 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.26 | 1 |
| Ascensia Diabetes Care US Inc. | $19.54 | 1 |
| Kyowa Kirin, Inc. | $19.01 | 1 |
| Abbott Laboratories | $16.59 | 1 |
| BETA BIONICS, INC. | $15.09 | 1 |
| Embecta Corp. | $13.84 | 1 |
By program year
Records — PY2024 (84)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.